The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016
K.L. Winthrop1, V. Strand2, D.M. Van Der Heijde3, P.J. Mease4, M.K. Crow5, M. Weinblatt6, J.M. Bathon7, M.H. Buch8, G.R. Burmester9, M. Dougados10, J. Kay11, X. Mariette12, F.C. Breedveld13, J.R. Kalden14, J.S. Smolen15, D.E. Furst16
- Oregon Health and Science University, Portland, OR, USA. firstname.lastname@example.org
- Stanford University School of Medicine, Portola Valley, CA, USA.
- Leiden University Medical Center, Meerssen, The Netherlands.
- Swedish Medical Center and University of Washington, Seattle, WA, USA.
- Hospital for Special Surgery, New York, NY, USA.
- Brigham and Women’s Hospital, Boston, MA, USA.
- Columbia University, New York, NY, USA.
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
- Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin; and German Rheumatism Research Center (Deutsches Rheumaforschungszentrum, DRFZ), Berlin, Germany.
- Hôpital Cochin, Paris, France.
- University of Massachusetts Medical School, Worcester, MA, USA.
- Paris-Sud University, Le Kremlin Bicetre, France.
- Leiden University Medical Center, Leiden, Netherlands.
- University of Erlangen, Erlangen, Germany.
- Vienna Medical Academy, Vienna, Austria.
- University of California, Los Angeles Medical Center, Los Angeles, CA, USA.
2016 Vol.34, N°4 ,Suppl.98
PI 0069, PF 0076
Free to view
(click on article PDF icon to read the article)
PMID: 27586809 [PubMed]
Accepted : 29/06/2016
In Press: 03/08/2016
The 18th annual international Targeted Therapies meeting brought together over 100 leading scientists and clinicians from around the world in the field of rheumatology. During the meeting, breakout sessions were held consisting of 5 disease-specific groups each with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/spondyloarthritis, systemic lupus erythematous, and other connective tissue diseases (e.g. Sjögren’s, Behçet’s, others). In each group, experts were asked to identify unmet needs in 3 categorical areas: basic/translational science, clinical science and therapeutic development, and clinical care. Needs were prioritised as primary or secondary. Overall, similar primary unmet needs were identified within each disease foci. Within translational science, these included the need for better understanding the heterogeneity within each disease, such that predictive tools for therapeutic response could be developed. Within clinical science and therapeutic trials, the ability to prevent progression to disease onset in those at risk, and the ability to cure disease were identified. A further unmet need was to develop new and accessible therapeutics, as well as to conduct strategic trials of currently approved therapies. Within the clinical care realm, improved co-morbidity management and patient-centered care were identified as unmet needs. Lastly, it was strongly felt there was a need to develop a scientific infrastructure for well-characterised, longitudinal cohorts married with biobanks and mechanisms to support data-sharing. This infrastructure could facilitate many of the unmet needs identified within each disease area.